研究者データベース


フリーワードで探す

全文検索となっています

難波 大夫ナニワ タイオ

所属部署医学研究科呼吸器・免疫アレルギー内科学分野
職名病院准教授
メールアドレス
ホームページURL
生年月日
Last Updated :2020/06/02

研究者基本情報

学歴

  • 1988年04月 - 1994年03月, 名古屋市立大学, 医学部

学位

  • 博士(医学)

所属学協会

  • 日本内科学会
  • 日本呼吸器学会
  • 日本リウマチ学会

経歴

  •   2016年04月 - 現在, 名古屋市立大学病院, リウマチ・膠原病内科, 部長
  •   2014年04月 - 現在, 名古屋市立大学大学院医学研究科, 呼吸器・免疫アレルギー内科学, 病院准教授
  •   2013年04月 - 2014年03月, 名古屋市立大学病院, 血液・膠原病内科, 副部長
  •   2013年04月 - 2014年03月, 名古屋市立大学大学院医学研究科, 腫瘍・免疫内科学, 病院准教授
  •   2007年04月 - 2013年03月, 名古屋市立大学大学院医学研究科, 腫瘍・免疫内科学, 助教
  •   2004年04月 - 2007年03月, 名古屋市立大学大学院医学研究科, 臨床分子内科学, 助手
  •   2001年07月 - 2004年03月, 名古屋市立大学, 第2内科, 臨床研究医
  •   1998年07月 - 2001年06月, 豊川市民病院, 内科
  •   1996年01月 - 1998年06月, 名古屋市立城北病院, 内科
  •   1994年04月 - 1995年12月, 名古屋市立大学病院, 第2内科, 臨床研修医

研究活動情報

研究分野

  • ライフサイエンス, 膠原病、アレルギー内科学

研究キーワード

    膠原病, 関節リウマチ

論文

  • Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: A large-scale multicentre cohort study, Yuko Kaneko, Takahiro Nunokawa, Yoshinori Taniguchi, Yukie Yamaguchi, Takahisa Gono, Kenichi Masui, Atsushi Kawakami, Yasushi Kawaguchi, Shinji Sato, Masataka Kuwana, Yutaka Okano, Naoshi Nishina, Maasa Tamura, Yohei Kirino, Kei Ikeda, Jun Kikuchi, Makoto Kubo, Yoshinori Tanino, Shinjiro Kaieda, Taio Naniwa, Masaki Watanabe, Tatsuhiko Harada, Taro Ukichi, Taisuke Kazuyori, Hideto Kameda, Makoto Kaburaki, Yasuo Matsuzawa, Shunji Yoshida, Yasuko Yoshioka, Takuya Hirai, Katsuaki Asakawa, Yoko Wada, Koji Ishii, Sakuhei Fujiwara, Takeshi Saraya, Kozo Morimoto, Tetsu Hara, Hiroki Suzuki, Hideki Shibuya, Yoshinao Muro, Ryoichi Aki, Takuo Shibayama, Shiro Ohshima, Yuko Yasuda, Masaki Terada, Yoshie Kawahara, Rheumatology (United Kingdom), 59, (1) 112 - 119,   2020年01月01日, 査読有り, © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation-associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γantibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.
  • Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: an observational study in routine clinical care., Naniwa T, Iwagaitsu S, Kajiura M, Modern rheumatology, 1 - 27,   2019年12月, 査読有り
  • Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study., Ohmura SI, Naniwa T, Tamechika SY, Miyamoto T, Shichi D, Kazawa N, Iwagaitsu S, Maeda S, Wada JI, Niimi A, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 25, (4) 253 - 261,   2019年04月, 査読有り
  • Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research., Maeda S, Osaga S, Maeda T, Takeda N, Tamechika SY, Naniwa T, Niimi A, PloS one, 14, (11) ,   2019年, 査読有り
  • Systematic Review and Meta-analysis for 2017 Clinical Practice Guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the Management of ANCA-associated Vasculitis., Nagasaka K, Harigai M, Hagino N, Hara A, Horita T, Hayashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S, Naniwa T, Sada KE, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimura Y, Modern rheumatology, 1 - 31,   2018年07月, 査読有り
  • Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial., Tamechika SY, Sasaki K, Hayami Y, Ohmura SI, Maeda S, Iwagaitsu S, Naniwa T, Archives of osteoporosis, 13, (1) ,   2018年06月, 査読有り
  • Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors., Naniwa T, Iwagaitsu S, Kajiura M, International journal of rheumatic diseases, 21, (3) 673 - 687,   2018年03月, 査読有り
  • Initial predictors of poor survival in myositisassociated interstitial lung disease: A multicentre cohort of 497 patients, Sato, S., Masui, K., Nishina, N., Kawaguchi, Y., Kawakami, A., Tamura, M., Ikeda, K., Nunokawa, T., Tanino, Y., Asakawa, K., Kaneko, Y., Gono, T., Ukichi, T., Kaieda, S., Naniwa, T., Kuwana, M., Okano, Y., Yamaguchi, Y., Taniguchi, Y., Kikuchi, J., Kubo, M., Watanabe, M., Harada, T., Kazuyori, T., Kameda, H., Kaburaki, M., Matsuzawa, Y., Yoshida, S., Yoshioka, Y., Hirai, T., Wada, Y., Ishii, K., Fujiwara, S., Saraya, T., Morimoto, K., Hara, T., Suzuki, H., Shibuya, H., Muro, Y., Aki, R., Shibayama, T., Ohshima, S., Yasuda, Y., Terada, M., Kawahara, Y., Rheumatology (United Kingdom), 57, (7) ,   2018年, 査読有り
  • Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis, Atsuko Iwai, Taio Naniwa, Shinya Tamechika, Shinji Maeda, MODERN RHEUMATOLOGY, 27, (3) 529 - 532,   2017年, 査読有り, We report on a 41-year-old woman with refractory systemic lupus erythematosus with massive pericarditis, macrophage activation syndrome, and glomerulonephritis despite high-dose glucocorticoids and tacrolimus. Tocilizumab dramatically improved pericarditis, and glomerulonephritis was controlled after adding cyclophosphamide. We had to halt tocilizumab and cyclophosphamide due to possible pneumocystis infection after five and three infusions of tocilizumab and intravenous cyclophosphamide, respectively. Nevertheless, no lupus flare had been observed on glucocorticoid monotherapy and enabled further rapid tapering prednisolone.
  • Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission, Taio Naniwa, Shiho Iwagaitsu, Mikiko Kajiura, MODERN RHEUMATOLOGY, 27, (1) 29 - 34,   2017年01月, 査読有り, Objectives: To describe the efficacy of adding tacrolimus to maintain remission in patients with rheumatoid arthritis (RA) on methotrexate after discontinuation of tumor necrosis factor inhibitor (TNFi) therapy. Methods: Consecutive patients with RA, who resumed a TNFi to treat flares after initial TNFi-free remission and discontinued a TNFi again after achieving remission and adding tacrolimus were enrolled. The lengths of remission after discontinuation of TNFi without or with tacrolimus were analyzed. Results: Thirteen TNFi-free periods in six patients, in which seven were without and six were with tacrolimus were analyzed. All were seropositive females with a median age of 46 years and symptom duration of 1.2 years at the onset of TNFi therapy. Two were treated with infliximab and four were with etanercept. The median dose of tacrolimus was 2mg/day with trough level of 4.5ng/ml. The length of time to flare after discontinuation of TNFi therapy with tacrolimus was significantly longer than those without tacrolimus (median 107 weeks [range 4-207] versus 13 weeks [2-36]). After adding tacrolimus, only one patient resumed TNFi therapy and three had no flare until final observation. Conclusions: Add-on tacrolimus was effective in maintaining TNFi-free remission in patients with RA who ever relapsed after TNFi-free remission.
  • Improvement of Arterial Wall Lesions in Parallel with Decrease of Plasma Pentraxin-3 Levels in a Patient with Refractory Takayasu Arteritis after Treatment with Tocilizumab., Iwagaitsu S, Naniwa T, Case reports in rheumatology, 2017,   2017年, 査読有り
  • Signs of forefeet joint synovitis have a limited impact on patient's perception of rheumatoid arthritis disease activity and acute-phase reactants, Taio Naniwa, Shiho Iwagaitsu, Shinya Tamechika, Shinji Maeda, Akio Niimi, MODERN RHEUMATOLOGY, 26, (2) 200 - 205,   2016年, 査読有り, Objectives. To determine the prevalence and distribution of signs of synovitis in the residual joints in remission defined by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) rheumatoid arthritis (RA) remission criteria and the role of their components in preventing misclassification due to reduced joint count. Methods. The cross-sectional observational data of RA patients including full joint counts were analyzed. Definitions of remission used were the ACR/EULAR RA remission criteria and their modifications using full joint counts with the same thresholds of the items and the calculated results. Results. A total of 304 RA patients with 3,149 observations could be analyzed. Patients in remission according to the ACR/EULAR remission criteria can still show residual disease activity in the feet in up to 27% of the population with a 28-joint count remission. Residual disease activity has no impact on patient's global assessment for current disease activity, when signs of concomitant ankle joint synovitis were absent. Conclusions. RA patients in remission according to the ACR/EULAR definitions can still show signs of synovitis mostly in the forefeet joints. Acute-phase reactants and patient's global assessment for current disease activity have little impact in mitigating the limitation of reduced joint count.
  • A comparative analysis of two interferon-γ releasing assays to detect past tuberculosis infections in Japanese rheumatoid arthritis patients., Iwagaitsu S, Naniwa T, Maeda S, Tamechika S, Nobata H, Imai H, Niimi A, Banno S, Modern rheumatology, 26, (5) 690 - 695,   2016年, 査読有り
  • Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes, Banno Shogo, Iwagaitsu Shiho, Naniwa Taio, Nobata Hironobu, Imai Hirokazu, Tamechika Shinya, Maeda Shinji, Niimi Akio, ARTHRITIS & RHEUMATOLOGY, 67,   2015年10月, 査読有り
  • Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents., Yamamoto K, Takeda Y, Takeda Y, Naniwa T, Narita H, Ohte N, BMC research notes, 7,   2014年06月, 査読有り
  • Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease, Taio Naniwa, Rei Ito, Maiko Watanabe, Yoshihito Hayami, Shinji Maeda, Kaneshige Sasaki, Shiho Iwagaitsu, CLINICAL RHEUMATOLOGY, 32, S103 - S106,   2013年03月, 査読有り, We report on a 64-year-old woman with multirefractory flare of adult-onset Still's disease successfully treated with six-month course of add-on anti-interleukin 6 receptor antibody, tocilizumab. Before administration of tocilizumab, the combination therapy with 80 mg/day of prednisolone and cyclosporine or tacrolimus for five weeks, two courses of pulse methylprednisolone, and high-dose intravenous immunoglobulin could not control the disease. Add-on tocilizumab dramatically improved her disease state and enabled tapering of corticosteroid and tacrolimus. Furthermore remission has been maintained on low-dose corticosteroid and tacrolimus after withdrawal of tocilizumab. This case report suggests that short-term add-on tocilizumab might be a useful therapeutic option for patients with multirefractory flare of polycyclic systemic adult-onset Still's disease.
  • Successful Use of Higher-Dose Etanercept for Multirefractory Systemic Flare of Adult-Onset Still's Disease with Liver Failure with No Response to Tocilizumab Therapy., Naniwa T, Tamechika S, Iwagaitsu S, Maeda S, Togawa H, Case reports in rheumatology, 2013,   2013年, 査読有り
  • Satisfaction and attitudes toward therapy in patients with rheumatoid arthritis, Nobuyuki Takahashi, Kaneshige Sasaki, Takeshi Nishiyama, Taio Naniwa, MODERN RHEUMATOLOGY, 22, (3) 376 - 381,   2012年06月, 査読有り, We examined associations between patient satisfaction and data obtained in routine clinical practice, and associations with therapeutic attitude in patients with rheumatoid arthritis (RA). A total of 220 patients with RA were enrolled in this cross-sectional evaluation. Demographic data, current disease state of RA, history of adverse events and self-reported questionnaire of patient satisfaction, attitudes toward therapy and reasons for being unwilling to change therapy were collected and analyzed. Multiple linear regression was used to identify characteristics. Age, Stanford Health Assessment Questionnaire (HAQ) score, and a visual analogue scale score of general health were the dominant correlates of satisfaction. Among the participants, 70% reported that they would not want to change therapy. The main reasons given were satisfaction with the current disease state (58%) and concern about the risk of side effects if therapy were to be changed (34%). Patients who were unwilling to change therapy due to concerns about side effects of new drugs did not have a significantly higher frequency of a past history of side effects, but showed significantly higher disease activity and a lower level of satisfaction with therapy. To summarize, patient satisfaction was associated with the HAQ. Patients who worried about the risk of side effects showed poor physical function and higher disease activity.
  • The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis., Maeda S, Hayami Y, Naniwa T, Ueda R, International journal of rheumatology, 2012,   2012年, 査読有り
  • Long-term remission of pulmonary veno-occlusive disease associated with primary Sjögren's syndrome following immunosuppressive therapy., Naniwa T, Takeda Y, Modern rheumatology, 21, (6) 637 - 640,   2011年12月, 査読有り
  • Comparison of QuantiFERON-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients, Tomoyo Maeda, Shogo Banno, Shinji Maeda, Taio Naniwa, Yoshihito Hayami, Maiko Watanabe, Shigeki Sato, Ryzo Ueda, JOURNAL OF INFECTION AND CHEMOTHERAPY, 17, (6) 842 - 848,   2011年12月, 査読有り, The aim of the study was to compare the usefulness of the QuantiFERON-TB Gold (QFT-2G) with that of the tuberculin skin test (TST) for detecting previous infection of tuberculosis (TB) in Japanese rheumatoid arthritis (RA) patients. Before receiving biologic therapy, 97 RA patients were divided into two groups based on their chest computed tomography (CT) findings: the TB past infection group (n = 48), with old inflammatory changes due to prior pulmonary TB; and the non-TB infection group (n = 49), without such findings. The QFT-2G was not affected by methotrexate or prednisolone. Indeterminate results with a positive control had a low incidence (5.2%). A positive QFT-2G for the TB past infection group at cutoffs of 0.35 and 0.1 IU/ml (intermediate range) was seen in 5.8% and 20.8%, respectively. A TST > 20 mm was significantly higher in the non-TB infection group (31%) than in the TB past infection group (13%). The correlation between the QFT-2G and TST was poor among all patients. Disagreement between these tests in the non-TB infection group was caused by the false-positive TST induced by previous Bacillus Calmette-Gu,rin (BCG) vaccination. Only 12 (12.4%) of 97 patients had a positive QFT-2G (a parts per thousand yen0.1 IU/ml) and a negative TST (< 20 mm), but in this subgroup, a high incidence (10, 83.3%) was detected in the TB past infection group. QFT-2G may be a good alternative to the TST to evaluate previous TB infection when it is necessary to determine whether isoniazid (INH) prophylaxis is needed before biologic therapy is begun.
  • Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis, Maiko Watanabe, Shogo Banno, Kaneshige Sasaki, Taio Naniwa, Yoshihito Hayami, Ryuzo Ueda, MODERN RHEUMATOLOGY, 21, (2) 144 - 149,   2011年04月, 査読有り, Rheumatoid arthritis (RA) has many pulmonary manifestations, including bronchial abnormalities that can develop into Mycobacterium avium-complex (MAC) pulmonary disease (PD). MAC-PD can be lethal in patients receiving tumor necrosis factor-alpha blockers despite administration of antibiotics. Diagnosis of MAC-PD is often difficult, because MAC is an environmental organism. In this study, we investigated the usefulness of serodiagnosis of MAC-PD in RA patients by using an enzyme immunoassay (EIA) kit that detects anti-glycopeptidolipid (GPL) core antigen IgA antibodies. Antibody levels were measured in 63 patients with RA: 14 with MAC-PD plus 3 cultured nontuberculous mycobacteria (NTM) other than MAC, 16 with pulmonary abnormalities characterizing NTM but undetected in sputum culture, and 30 control subjects. RA patients with MAC-PD showed significantly higher antibody levels than controls (p = 0.02). The cutoff point was set at 0.7 IU/l, making the sensitivity and specificity of the antibody in MAC-PD and control patients 43% and 100%, respectively. The EIA kit is useful for diagnosis of MAC-PD in RA patients because of its high specificity. This test is an easier and less invasive form of examination and could therefore replace bronchoscopy as the main diagnostic procedure for RA patients with MAC-PD.
  • Reversible Cerebral Vasoconstriction Syndrome in a Patient with Takayasu's Arteritis, Yuto Uchida, Noriyuki Matsukawa, Takuya Oguri, Keita Sakurai, Toshiyasu Miura, Shiho Iwagaitsu, Taio Naniwa, Kosei Ojika, INTERNAL MEDICINE, 50, (15) 1611 - 1614,   2011年, 査読有り, We herein present the first reported case of reversible cerebral vasoconstriction syndrome (RCVS) in Takayasu's arteritis (TA), in a patient with severe thunderclap headache and generalized tonic-clonic seizure. Magnetic resonance imaging and angiography revealed posterior reversible encephalopathy syndrome, followed by severe vasoconstriction in multiple arteries. RCVS should be included in the differential diagnosis of thunderclap headache attacks with radiologic intracranial vascular abnormalities in connective tissue diseases, including TA.
  • Hepatitis B Virus-Related Polyarteritis Nodosa Presenting With Multiple Lung Nodules and Cavitary Lesions, Taio Naniwa, Tomoyo Maeda, Shigeki Shimizu, Rei Ito, CHEST, 138, (1) 195 - 197,   2010年07月, 査読有り, The patient presented here is a 59-year-old Japanese man with active chronic hepatitis B with precore and core promoter mutated virus, presenting with high fever, bloody sputum, and multiple lung nodules with excavation. Surgical biopsy of the lung nodule showed necrotizing vasculitis affecting pulmonary arteries without granulomatous changes. The pulmonary manifestations of this patient resembled Wegener granulomatosis. However, the pathologic findings showing nongranulomatous necrotizing vasculitis involving the small pulmonary arteries, presence of circulating immune complex, absence of antineutrophil cytoplasmic antibodies, and excellent response to the combination therapy of corticosteroid and an anti-hepatitis B virus agent, entecavir, led us to the diagnosis of hepatitis B virus-related polyarteritis nodosa (PAN). Radiographic evidence of lung nodules or cavitations seen in systemic vasculitis patients has been considered a sign suggestive of granulomatous disease and a diagnostic surrogate marker for necrotizing granulomatous vasculitis, but a clinical relevance to hepatitis B virus-related PAN has not been reported before this case. CHEST 2010; 138(1):195-197
  • Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection, Tomoyo Maeda, Shogo Banno, Shinji Maeda, Taio Naniwa, Yoshihito Hayami, Maiko Watanabe, Rei Itoh, Shigeki Sato, Ryuzo Ueda, MODERN RHEUMATOLOGY, 20, (1) 18 - 23,   2010年02月, 査読有り, We aimed to determine the sensitivity and specificity of QuantiFERON-TB Gold (QFT-G) in Japanese rheumatoid arthritis (RA) patients with a past history of tuberculosis (TB). We assessed whether it is possible to decrease the cutoff using receiver operating characteristic (ROC) analysis. We evaluated chest computed tomography (CT) findings, prior history of treatment, and contact with active TB in 370 RA patients. Forty-nine patients before initiation of treatment with tumor necrosis factor (TNF) inhibitors were divided into two groups: 22 with a past history of TB and 27 without. We estimated the efficacy of QFT-G compared with the tuberculin skin test and antituberculosis (anti-TB) glycolipid antigen antibody. QFT-G was positive (a parts per thousand yen0.35 IU/ml) in 13.6% with a past history of TB, increasing to 27.3% at the intermediate range cutoff of 0.1 IU/ml. The sensitivity and specificity of QFT-G was 0.27 and 1.00, respectively, at 0.1 IU/ml. Using ROC analysis, the area under the curve (AUC) of QFT-G but not for the other two tests was significantly large. QFT-G is a useful diagnostic method due to its superior specificity, but the use of a cutoff value of 0.35 IU/ml will likely result in an underestimate. We propose that a lower interferon-gamma (IFN-gamma) titer of 0.1 IU/ml be adopted when deciding to administer anti-TB drugs before initiation of TNF inhibitors.
  • Pulmonary Manifestations in Sjogren's Syndrome: Correlation Analysis Between Chest Computed Tomographic Findings and Clinical Subsets with Poor Prognosis in 80 Patients, Maiko Watanabe, Taio Naniwa, Masaki Hara, Toshinao Arakawa, Tomoyo Maeda, JOURNAL OF RHEUMATOLOGY, 37, (2) 365 - 373,   2010年02月, 査読有り, Objective. Sjogren's syndrome (SS) has a varied clinical spectrum and has been associated with various chest computed tomography (CT) findings. We Sought to delineate the characteristic CT features in various Subsets of SS, especially poor prognosis subsets. Methods. Retrospectively identified 80 never-smoker SS patients 156 primary SS (1-SS). 24 secondary SS (2-SS) who Underwent chest CT at our institution during a 3-year period from 2004 through 2007 were included in this study. Chest CT findings were qualitatively and semiquantitatively analyzed with comparison between 1-SS and 2-SS, and correlation with anti-SSB/La seropositivity and the presence of clonally derived lymphoproliferative disorder (cLPD), which are known to be pathognomonic and prognostic clinical features of SS patients. Results. All patients were women with median ape of 60 years. Anti-SSB/La antibodies were found in 17 primary SS patients and 4 2-SS patients. Eleven patients with cLPD were identified and all of them had 1-SS. The most frequent CT finding in both types of patients was interlobular septal thickening. Secondary SS was associated with a significantly greater frequency and extent of Extent,combing versus 1-SS. Univariate and multivariate analysis showed a significant association between honeycombing and 2-SS. In patients with 1-SS and in the SS group as a whole, we observed independent and significant associations between cysts and anti-SSB/La seropositivity or cLPD. Conclusion. Cysts are significantly associated with anti-SSB/La seropositivity and cLPD. The presence of lung cysts revealed by chest CT might be a prognostic clinical feature, a clue, or a predictor cLPD in patients with SS. (First Release Dec 15 2009; J Rheumatol 2010:37:365-73: doi: 10.3899/jrheum.090507)
  • Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies, Taio Naniwa, Maiko Watanabe, Shogo Banno, Tomoyo Maeda, RHEUMATOLOGY INTERNATIONAL, 29, (11) 1287 - 1291,   2009年09月, 査読有り, In the present study, we retrospectively evaluate the efficacy of low dose tacrolimus (TAC) as add-on therapy in refractory rheumatoid arthritis (RA) despite a combination of tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) using consecutive case series of five patients with active RA (mean disease duration 2.3 years) despite MTX and TNF inhibitors for at least 3 months (mean 9.5 months) treated with low dose TAC (1.5-2 mg/day) for at least 6 months (mean 1.8 years). Clinical and radiographic efficacy was assessed according to the European league against rheumatism response criteria and the modified Sharp method, respectively. At 1 year, three patients reached to remission. The mean yearly progression of radiographic joint damage of all five patients after the onset of TAC was significantly decreased compared to that observed during anti-TNF therapy without TAC (p = 0.04). One patient temporally discontinued the treatment because of herpes zoster. In RA patients with inadequate response to MTX and a TNF inhibitor, additions of low dose TAC markedly improved clinical variables including radiographic scores without remarkable detrimental effects. It seems that TAC in combination with MTX and TNF inhibitors may be a hopeful treatment option for RA patients with inadequate response to anti-TNF therapy.
  • [Efficacy of three-dimensional computed tomography for evaluating airway tract involvement in patients with relapsing polychondritis]., Watanabel M, Osawa T, Naniwa T, Torii S, Sanji H, Ninomiya S, Yoshinouchi T, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 46, (5) 363 - 367,   2008年05月, 査読有り
  • Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome., Takahashi N, Naniwa T, Banno S, Modern rheumatology, 18, (1) 72 - 75,   2008年, 査読有り
  • Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate., Naniwa T, Maeda T, Mizoshita T, Hayami Y, Watanabe M, Banno S, Ito R, Internal medicine (Tokyo, Japan), 47, (23) 2083 - 2085,   2008年, 査読有り
  • Drug-induced hypersensitivity syndrome associated with a marked increase in anti-paramyxovirus antibody titers in a scleroderma patient., Naniwa T, Maeda S, Sawada H, Watanabe Y, Osawa T, Hayami Y, Banno S, Morita A, Ueda R, Allergology international : official journal of the Japanese Society of Allergology, 56, (3) 303 - 308,   2007年09月, 査読有り
  • Expression of chemokine receptors CXCR3 and CCR4 in lymphocytes of idiopathic nonspecific interstitial pneumonia, Takeo Yoshinouchi, Taio Naniwa, Shigeki Shimizu, Yuji Ohtsuki, Jiro Fujita, Shigeki Sato, Tadaaki Eimoto, Ryuzo Ueda, RESPIRATORY MEDICINE, 101, (6) 1258 - 1264,   2007年06月, 査読有り, Little is known about the role of chemokines and their receptors interaction, which are essential for recruitment of selective lymphocyte subsets during inflammation, in the pathogenesis of idiopathic nonspecific interstitial pneumonia (NSIP). Recent studies have revealed Th1 and Th2 cells preferentially employ the chemokine receptors, CXCR3 and CCR4, respectively, in the process of accumulation into inflammatory sites. We evaluated the CXCR3 and CCR4 expression on infiltrated Lymphocytes in lung tissues of 12 NSIP cases and 10 idiopathic pulmonary fibrosis (IPF) cases in our previous study. The number of CXCR3 positive lymphocytes of NSIP patients was significantly greater than that of IPF patients (261.1 +/- 145.1 vs. 64.9 +/- 27.0, P < 0.01). The number of CCR4 positive lymphocytes of NSIP patients was significantly lower than that of IPF (9.5 +/- 8.3 vs.62.6 +/- 26.9, P < 0.01). The CXCR3 to CCR4 ratio of NSIP patients was significantly greater than that of IPF patients (47.9 +/- 45.9 vs. 1.11 +/- 0.40, P < 0.01). The differences of CXCR3 positive, CCR4 positive Lymphocyte counts, and of CXCR3/CCR4 ratio between cellular and fibrosing NSIP were not significant. These results suggest that a Th1 pattern of chemokine receptor expression predominates in the lung interstitium of patients with NSIP but, in IPF patients, CCR4 might be relatively predominant, in contrast to the finding in NSIP patients, and that Th1/Th2 balance might be an important factor in the pathogenesis of NSIR (c) 2006 Elsevier Ltd. All rights reserved.
  • Pulmonary-renal syndrome in systemic sclerosis: a report of three cases and review of the literature., Naniwa T, Banno S, Sugiura Y, Yokota K, Oosawa T, Maeda S, Hayami Y, Takahashi N, Ueda R, Matsumoto Y, Modern rheumatology, 17, (1) 37 - 44,   2007年, 査読有り
  • Normotensive scleroderma renal crisis with diffuse alveolar damage after corticosteroid therapy., Naniwa T, Banno S, Takahashi N, Maeda S, Hayami Y, Ueda R, Modern rheumatology, 15, (2) 134 - 138,   2005年, 査読有り
  • Distribution of CXCR3- or CCR4-positive cells in interstitial pneumonia associated with primary Sjogren's syndrome, S Shimizu, T Yoshinouchi, T Naniwa, M Nakamura, S Sato, Y Ohtsuki, J Fujita, Yamadori, I, T Eimoto, R Ueda, VIRCHOWS ARCHIV, 445, (5) 477 - 484,   2004年11月, 査読有り, Patients with primary Sjogren's syndrome ( SS) occasionally develop interstitial pneumonia (SS-IP), the prognosis of which is less grave compared with that of idiopathic pulmonary fibrosis (IPF). We examined distribution of helper T-cell subsets in open lung biopsy specimens from seven patients with SS-IP and, for comparison, ten patients with IPF. The expression of CXCR3 and CCR4, chemokine receptors associated in vitro with Th1 and Th2 cells, respectively, was analyzed in the mononuclear infiltrate using immunohistochemistry. The expression of CD4, CD8, and CD20 in the infiltrate was similarly examined. The positive cells were semiquantified in fibrosing areas and lymphoid clusters of both SS-IP and IPF. In fibrosing areas, CXCR3-positive cells were dominant over CCR4-positive cells in all cases of SS-IP, whereas the two types of cells showed no such difference in cases of IPF. Each of the CXCR3/CD4 and CXCR3/ CCR4 ratios was significantly higher in SS-IP than in IPF ( P< 0.05 and P< 0.05, respectively). The CCR4/CD4 ratio showed a significantly lower value in SS-IP than in IPF ( P< 0.05). In lymphoid clusters, prominent in SS-IP and few and small in IPF, CXCR3-positive cells predominated over CCR4-positive cells in both lung lesions. There was no significant difference of CXCR3/ CCR4 ratio in lymphoid clusters between SS-IP and IPF ( P= 0.33). These findings in SS-IP are in accordance with those reported in previous studies of the salivary glands of SS patients, where most of the infiltrating lymphocytes expressed CXCR3, and the expression of interferon-gamma was upregulated. In contrast, the Th2 cell dominance was reported in IPF in the previous studies. The present findings suggest that the pathogenesis of interstitial pneumonia is different between SS-IP and IPF in regard to the roles of helper T-cell subsets.
  • Microscopic polyangiitis associated with diffuse panbronchiolitis., Park J, Banno S, Sugiura Y, Yoshikawa K, Naniwa T, Wakita K, Hayami Y, Sato S, Ueda R, Internal medicine (Tokyo, Japan), 43, (4) 331 - 335,   2004年04月, 査読有り
  • Transforming growth factor beta 1 gene polymorphism in patients with systemic sclerosis, Y Sugiura, S Banno, Y Matsumoto, T Niimi, T Yoshinouchi, Y Hayami, T Naniwa, R Ueda, JOURNAL OF RHEUMATOLOGY, 30, (7) 1520 - 1523,   2003年07月, 査読有り, Objective. To determine whether transforming growth factor beta1 (TGFbeta1) gene DNA polymorphism is associated with pathogenesis in the fibrosis of patients with systemic sclerosis (SSc). Methods. Eighty-seven Japanese patients with SSc including 30 with diffuse type and 57 with limited type together with 110 unrelated controls were investigated. Pulmonary fibrosis was determined in 34 SSc patients using high-resolution chest computed tomography. TGFBI genetic polymorphisms were analyzed in 2 loci; T869C (Leu10Pro) in codon 10 at exon 1, and C-509T in the promoter region using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results. Neither the genotype of T/C polymorphism in T869C nor C/T polymorphism in C-509T revealed any difference in distribution between SSc and controls. In the group of SSc patients with pulmonary fibrosis, a weak but significantly high frequency (p = 0.05) of TC+CC (the presence of C allele) in T869C, and CT+TT (the presence of T allele) in C-509T was found. Compared with controls, the pulmonary fibrosis group showed no difference in the highly frequent alleles. Conclusion. Our results suggest that TGFBI polymorphisms do not play a role in the pathogenesis of SSc, even though there remains the possibility of a risk factor for genetic susceptibility to pulmonary fibrosis.
  • [A case of sarcoidosis with rheumatic features (Löfgren's syndrome)]., Niimi T, Sato S, Sugiura Y, Akita K, Maeda H, Ninomiya S, Achiwa H, Masui S, Bessho Y, Maeno K, Naniwa T, Kotsuka M, Morishita M, Ueda R, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 41, (3) 207 - 210,   2003年03月, 査読有り
  • [Recurrence of thymoma accompanied with hypogammaglobulinemia 20 years after surgery: a case report]., Naniwa T, Kakihara H, Zen-nami S, Tomita H, Sugiura Y, Yoshinouchi T, Sato S, Ueda R, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 40, (3) 241 - 244,   2002年03月, 査読有り
  • [Adenocarcinoma of the lung with skeletal muscle metastasis, resulting in death due to myocardial metastasis: a case report]., Naniwa T, Kakihara H, Tomita H, Sugiura Y, Yoshinouchi T, Sato S, Ueda R, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 40, (2) 140 - 144,   2002年02月, 査読有り
  • [Successful use of immunosuppressive agents for the treatment of progressive rheumatoid interstitial lung disease: a case report]., Naniwa T, Tomita H, Ninomiya S, Mori T, Maeda S, Kawaguchi H, Sugiura Y, Yoshinouchi T, Morishita M, Ueda R, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 40, (1) 55 - 60,   2002年01月, 査読有り

MISC

  • 抗インターロイキン6受容体抗体投与後に重篤な肝障害増悪を伴って急性増悪した関節リウマチに伴うマクロファージ活性化症候群の1例, 山邊徹, 大村晋一郎, 上原幸治, 為近真也, 岩垣津志穂, 前田伸治, 難波大夫, 中部リウマチ, 48, (2) 18 - 18,   2019年03月
  • HLA-B52陽性であった壊疽性膿皮症に高安動脈炎が合併した1例, 加納 慎二, 西田 絵美, 小林 由佳, 鳥居 寛, 森田 明理, 山邉 徹, 難波 大夫, 日本皮膚科学会雑誌, 129, (2) 224 - 224,   2019年02月
  • 慢性緑膿菌感染が膠原病患者におけるアミロイドーシスの発症,増悪に寄与したと考えられた2例, 山邊徹, 前田伸治, 和田洵一, 上原幸治, 爲近真也, 大村晋一郎, 岩垣津志穂, 難波大夫, 新実彰男, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62nd,   2018年03月20日
  • 心室頻拍を呈した心筋炎合併多発性筋炎の1例, 和田 洵一, 爲近 真也, 山邊 徹, 大村 晋一郎, 岩垣津 志穂, 前田 伸治, 難波 大夫, 新実 彰男, 中部リウマチ, 47, (2) 23 - 23,   2018年03月
  • 関節リウマチの治療10:有効性・寛解 実臨床下における関節リウマチにおけるTNF阻害薬フリー寛解維持後のメトトレキサート治療減弱の実態, 難波 大夫, 岩垣津 志穂, 梶浦 美希子, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回,   2018年03月
  • 悪性腫瘍関連筋炎に合併した嚥下障害の予後の検討, 大村 晋一郎, 宮本 俊明, 和田 洵一, 上原 幸治, 山邊 徹, 為近 真也, 岩垣津 志穂, 前田 伸治, 難波 大夫, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回,   2018年03月
  • 日本人悪性腫瘍関連筋炎における長期生命予後の検討 多発性筋炎、皮膚筋炎における後ろ向き研究、241例における検討, 大村 晋一郎, 宮本 俊明, 和田 洵一, 山邊 徹, 上原 幸治, 為近 真也, 岩垣津 志穂, 前田 伸治, 難波 大夫, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回,   2018年03月
  • 関節リウマチや分類不能関節炎における寛解達成率および寛解維持による治療減弱 血清反応別による比較, 岩垣津 志穂, 難波 大夫, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回,   2018年03月
  • 慢性緑膿菌感染が膠原病患者におけるアミロイドーシスの発症、増悪に寄与したと考えられた2例, 山邊 徹, 前田 伸治, 和田 洵一, 上原 幸治, 爲近 真也, 大村 晋一郎, 岩垣津 志穂, 難波 大夫, 新実 彰男, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回,   2018年03月
  • 【関節リウマチ治療の新しいエビデンス】 発症早期関節リウマチの初期治療におけるグルココルチコイド併用DMARD 3剤併用療法の有用性-tREACH trialの結果から, 難波 大夫, リウマチ科, 59, (3) 273 - 280,   2018年03月
  • 【筋病変を伴うリウマチ性疾患の診断と治療】 多発性筋炎・皮膚筋炎に伴う悪性腫瘍, 大村 晋一郎, 為近 真也, 難波 大夫, リウマチ科, 59, (1) 26 - 33,   2018年01月
  • マクロファージ活性化症候群を合併した全身性エリテマトーデス患者血清における多項目サイトカイン解析, 爲近 真也, 前田 伸治, 和田 洵一, 大村 晋一郎, 岩垣津 志穂, 前田 智代, 難波 大夫, 新実 彰男, 日本臨床免疫学会会誌, 40, (4) 303 - 303,   2017年08月
  • 頸動脈間隙に生じた占拠性病変により嚥下障害を急性発症した抗好中球細胞質抗体(ANCA)関連血管炎患者の2例, 爲近 真也, 難波 大夫, 和田 洵一, 大村 晋一郎, 岩垣津 志穂, 前田 伸治, 中部リウマチ, 46, (2) 39 - 40,   2017年03月
  • 多発性筋炎・皮膚筋炎 ステロイド治療抵抗性抗SRP抗体陽性筋炎に対する大量ガンマグロブリン療法(IVIG)の有効性の検討, 大村 晋一郎, 為近 真也, 和田 洵一, 岩垣津 志穂, 前田 伸治, 難波 大夫, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回,   2017年03月
  • 多発性筋炎・皮膚筋炎 嚥下障害を合併したステロイド治療抵抗性多発性筋炎(PM)/皮膚筋炎(DM)に対する大量ガンマグロブリン療法(IVIG)の有効性の検討, 大村 晋一郎, 宮本 俊明, 為近 真也, 和田 洵一, 岩垣津 志穂, 前田 伸治, 難波 大夫, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回,   2017年03月
  • CTLA4-Ig(Abatacept)によるリウマチ患者CD4+T cell subsetの細胞増殖(Ki67発現)へ及ぼす効果の検討, 前田 伸治, 前田 智代, 爲近 真也, 大村 晋一郎, 岩垣津 志穂, 難波 大夫, 新実 彰男, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回,   2017年03月
  • 高齢で発症した関節リウマチおよび分類不能関節炎の臨床的検討, 岩垣津 志穂, 和田 洵一, 爲近 真也, 大村 晋一郎, 前田 伸治, 難波 大夫, 新実 彰男, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回,   2017年03月
  • リツキシマブにて寛解導入したSjoegren症候群関連難治性II型クリオグロブリン血管炎の1例, 和田 洵一, 爲近 真也, 大村 晋一郎, 岩垣津 志穂, 前田 伸治, 難波 大夫, 新実 彰男, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回,   2017年03月
  • P1-21 マクロファージ活性化症候群を合併した全身性エリテマトーデス患者血清における多項目サイトカイン解析, 爲近 真也, 前田 伸治, 和田 洵一, 大村 晋一郎, 岩垣津 志穂, 前田 智代, 難波 大夫, 新実 彰男, 日臨免誌, 40, (4) 303a - 303a,   2017年, <p>【背景】全身性エリテマトーデス(SLE)は,多彩な臨床症状・免疫異常・多臓器障害を呈する全身性自己免疫疾患であり,ときに重篤なマクロファージ活性化症候群(MAS)を合併する.【目的・方法】SLEおよび合併MAS病態の炎症病態の解明のため,当院を受診(2011/3月から2015/1月)したMAS合併SLE患者6例と治癒後MAS合併SLE患者5例,および高活動性SLE患者(SELENA-SLEDAI 10以上で尿蛋白2+以上の活動期ループス腎炎)4例,低活動性SLE患者(プレドニゾロン10 mg/日以下でSELENA-SLEDAI 5以下)9例,健常人4例の血清を用いてmultiplex ELISA(Q-PlexTM Array(QUANSYS Biosciences))により16種類のサイトカインを測定した.また,SLEと同様に自己免疫性MASを合併することが知られる成人発症スティル病(AOSD,ferritin 1000 ng/mL以上)患者6例の血清サイトカインも測定した.【結果】MAS治療後や低活動性SLEと比べ,MAS合併SLEではIL-6, IL-8, IL-15, TNF-αが有意に高値であった.高活動性SLEでも同様のサイトカイン上昇が認められたが,IL-15はMAS合併SLEにおいて有意に高値であり,AOSDにおいても同様にIL-15は高値であった.【結語】MAS合併SLEにおいて,IL-6, IL-8, IL-15, TNF-αが有意に上昇し,特にIL-15は自己免疫性MAS病態において有意に高値であった.</p>
  • 子宮卵巣原発癌性胸膜・心膜炎を疑われたIgG4関連疾患の1例, 何澤信礼, 河合辰哉, 浦野みすぎ, 芝本雄太, 大久保仁嗣, 宮崎幹規, 新実彰男, 為近真也, 難波大夫, 日本医学放射線学会秋季臨床大会抄録集, 52nd,   2016年08月29日
  • 【関節リウマチ診療における新たな課題】 生物学的製剤効果不十分・二次無効の対策(DMARD追加、分子標的薬へのスイッチなど), 難波 大夫, リウマチ科, 55, (5) 480 - 487,   2016年05月
  • 頸動脈間隙に生じた占拠性病変により嚥下障害を急性発症した抗好中球細胞質抗体(ANCA)関連血管炎患者の2例, 爲近 真也, 難波 大夫, 和田 洵一, 大村 晋一郎, 岩垣津 志穂, 前田 伸治, 新実 彰男, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回,   2016年03月
  • 血中膵酵素値上昇が持続したループス腸炎の1例, 和田 洵一, 爲近 真也, 大村 晋一郎, 岩垣津 志穂, 前田 伸治, 難波 大夫, 中部リウマチ, 45, (1) 51 - 51,   2015年08月
  • 側頭動脈生検にて側頭動脈炎の診断に至った11例, 村嶋 寛子, 西田 絵美, 渡辺 正一, 加藤 裕史, 新谷 洋一, 古橋 卓也, 爲近 真也, 前田 伸治, 難波 大夫, 森田 明理, 日本皮膚科学会雑誌, 125, (4) 901 - 901,   2015年04月
  • 嚥下障害を合併した抗SRP抗体陽性筋症に対して大量γグロブリン療法が有効であった一例, 大村晋一郎, 宮本俊明, 和田洵一, 為近真也, 岩垣津志穂, 前田伸治, 難波大夫, 日本臨床リウマチ学会プログラム・抄録集, 30th,   2015年
  • 造影CTおよび3D-CT Angiographyを用いた大動脈炎症候群(高安病)画像所見の検討 (胸部の最新画像情報2015), 何澤 信礼, 為近 真也, 難波 大夫, 臨床放射線, 60, (1) 172 - 183,   2015年01月
  • 治療抵抗性重症成人スチル病2例に対する生物学製剤治療の検討, 爲近 真也, 岩垣津 志穂, 前田 伸治, 速水 芳仁, 難波 大夫, 中部リウマチ, 44, (1) 54 - 54,   2014年07月
  • 全身性エリテマトーデスに発症したマクロファージ活性化症候群に対しエタネルセプトが著効した1例, 小林 彩子, 爲近 真也, 岩垣津 志穂, 前田 伸治, 速水 芳仁, 難波 大夫, 中部リウマチ, 44, (1) 57 - 58,   2014年07月
  • 関節リウマチにおける結核リスク評価のためのクォンティフェロンTBゴールドとT-SPOT TBの有用性, 岩垣津 志穂, 坂野 章吾, 難波 大夫, 爲近 真也, 野畑 宏信, 今井 裕一, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回,   2014年03月
  • インフリキシマブの投与時間短縮を行なった関節リウマチ患者における投与時反応発現率についての検討, 岩垣津 志穂, 難波 大夫, 速水 芳仁, 前田 伸治, 爲近 真也, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回,   2013年03月
  • 治療抵抗性心外膜炎、マクロファージ活性化症候群および糸球体腎炎にトシリズマブが異なる臨床効果を示した全身性エリテマトーデスの一例, 岩井 敦子, 小林 彩子, 爲近 真也, 前田 伸治, 速水 芳仁, 岩垣津 志穂, 難波 大夫, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回,   2013年03月
  • 全身性エリテマトーデスに併発したクローン病に対しアダリムマブが著効した1例, 爲近 真也, 岩垣津 志穂, 前田 伸治, 速水 芳仁, 難波 大夫, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回,   2013年03月
  • エタネルセプトによる皮膚血管炎が疑われた関節リウマチの1例, 伊藤 礼, 坂野 章吾, 渡辺 舞子, 難波 大夫, 速水 芳仁, 金子 夏美, 森田 明理, 中部リウマチ, 41, (2) 100 - 100,   2012年07月
  • 多発性筋炎・皮膚筋炎(1) 皮膚筋炎・多発性筋炎におけるシクロスポリンやタクロリムスの有用性に関する検討, 爲近 真也, 岩垣津 志穂, 渡辺 舞子, 前田 伸治, 速水 芳仁, 難波 大夫, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回,   2012年03月
  • 関節リウマチの治療の寛解基準 関節リウマチ(RA)の寛解評価におけるバイオマーカーの診断精度, 難波 大夫, 岩垣津 志穂, 前田 伸治, 速水 芳仁, 爲近 真也, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回,   2012年03月
  • 当院におけるベーチェット病の臨床的特徴, 速水 芳仁, 爲近 真也, 岩垣津 志穂, 前田 伸治, 難波 大夫, 坂野 章吾, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回,   2012年03月
  • 膠原病患者におけるスルファメトキサゾール・トリメトプリム(SMX-TMP)の薬物特異体質的有害事象についての検討, 岩垣津 志穂, 難波 大夫, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回,   2012年03月
  • 大動脈炎症候群の治療経過中にReversible cerebral vasoconstriction syndrome(RCVS)を来たした1例, 打田 佑人, 小栗 卓也, 三浦 敏靖, 匂坂 尚史, 大喜多 賢治, 松川 則之, 小鹿 幸生, 岩垣津 志穂, 難波 大夫, 櫻井 圭太, 臨床神経学, 51, (6) 441 - 441,   2011年06月
  • 多発性筋炎・皮膚筋炎 皮膚筋炎・多発性筋炎における悪性腫瘍合併に関する検討, 爲近 真也, 難波 大夫, 前田 伸治, 渡辺 舞子, 佐々木 謙成, 岩垣津 志穂, 速水 芳仁, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回,   2011年06月
  • 可逆性脳血管攣縮症候群を発症した大動脈炎症候群の1例, 岩垣津 志穂, 難波 大夫, 佐々木 謙成, 渡辺 舞子, 前田 伸治, 速水 芳仁, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回,   2011年06月
  • 当院早期関節リウマチ外来における関節リウマチの治療目標達成率の検討, 難波 大夫, 佐々木 謙成, 岩垣津 志穂, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回,   2011年06月
  • 結節性多発動脈炎とバージャー病との鑑別を要し、下肢切断に至った1例, 前田 智代, 坂野 章吾, 伊藤 礼, 渡辺 舞子, 難波 大夫, 速水 芳仁, 竹内 藍子, 古橋 卓也, 新谷 洋一, 森田 明理, 中部リウマチ, 40, (2) 123 - 123,   2010年12月
  • 【内科医が診る関節リウマチ State of Art】 臓器合併症に対する対処法 血管病変, 難波 大夫, 坂野 章吾, 内科, 103, (4) 680 - 683,   2009年04月, リウマトイド血管炎は、進行した関節リウマチ(RA)患者にみられる重要な関節外病変の一つであり、全身動脈炎型から末梢動脈炎型まで幅広い臨床像を呈する病態には免疫複合体の関与が示唆され、血管炎性ニューロパチーや皮膚病変などを呈し、間質性肺炎など複数の関節外病変を伴う。診断プロセスには類似症状をきたしうる諸病態の鑑別と、罹患臓器の生検による組織診断が重要である。治療は抗リウマチ薬(DMARDs)による治療に加え、重症度に応じて副腎皮質ステロイドを主とし、免疫抑制薬、血漿交換などを併用し加療する。治療抵抗性の重症リウマトイド血管炎へのTNF阻害薬の有効性が示され、今後、治療におけるキードラッグになる可能性がある。(著者抄録)
  • プライマリ・ケアにおける疼痛疾患の診断, 石塚 達夫, 福沢 嘉孝, 牛越 博昭, 川田 憲一, 長浜 貴彦, 難波 大夫, 宮崎 仁, 日本内科学会雑誌, 98, (2) 429 - 436,   2009年02月
  • 気道病変の評価に3D-CTが有用であった再発性多発軟骨炎の2症例, 渡辺 舞子, 大澤 智代, 難波 大夫, 鳥居 貞和, 三治 宏司, 二宮 茂光, 吉野内 猛夫, 日本呼吸器学会雑誌, 46, (5) 363 - 367,   2008年05月, 再発性多発軟骨炎(relapsing polychondritis:RP)の気道病変は重要な予後因子の一つであり経時的な評価が必要であるが、気管支鏡検査等の侵襲的検査は気道病変を増悪する可能性がある。我々はRP2症例に対し非侵襲性検査として3D-CTを用い、気道病変の評価に有効と考えられたため、文献的考察を含め報告する。症例は31歳男性と78歳女性。1例目はステロイド、免疫抑制剤で治療を受けていたが自己中断していた。2例目はステロイド治療中であった。いずれも肺炎を合併し入院。気道病変の非侵襲性検査として3D-CTを施行し、共通所見として、気管・両主気管支の扁平化を認めた。RPの気道病変の非侵襲的検査として3D-CTが有用と考えられた。(著者抄録)
  • Wegener肉芽腫・サルコイドーシスと鑑別を要した後期梅毒の1例, 佐々木 謙成, 速見 芳仁, 難波 大夫, 坂野 章吾, 上田 龍三, 磯貝 善蔵, 森田 明理, 松本 美富士, 中部リウマチ, 35, (2) 171 - 171,   2004年07月
  • ロイコトリエン拮抗薬内服中に発症したChurg-Strauss症候群の1例, 渡辺 正一, 磯村 巌, 難波 大夫, 森田 明理, 日本皮膚科学会雑誌, 114, (5) 991 - 995,   2004年04月, 49歳男性.1999年に気管支喘息を発症し,吸入ステロイド,ロイコトリエン(LT)拮抗薬により加療されていた.2002年7月上旬より両手背腫脹が出現した.末梢血上好酸球の上昇を認め,四肢・左側腹部の紫斑を伴うようになったため,皮膚科受診となった.皮膚病理組織像でフィブリノイドの沈着を含む血管炎の所見が得られ,臨床像と併せChurg-Strauss症候群と診断した.入院後ステロイドパルス療法とプレドニゾロン30 mg/日内服療法により紫斑・末梢血好酸球・CRPの改善を認めた.近年LT拮抗薬内服中にChurg-Strauss症候群を発症した症例が報告されるようになりその因果関係に関心が高まっている.本症例では3種類のLT拮抗薬内服後にChurg-Strauss症候群を発症していることから,本症とLT拮抗薬との関連が示唆された.
  • Wegener肉芽腫・サルコイドーシスと鑑別を要した後期梅毒の1例, 速水 芳仁, 難波 大夫, 坂野 章吾, 上田 龍三, 磯貝 善蔵, 森田 明理, 松本 美富士, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 48回,   2004年03月
  • 化学物質の曝露を認めた好酸球性筋膜炎の1例, 脇田 香里, 坂野 章吾, 難波 大夫, 速水 芳仁, 上田 龍三, 磯貝 善蔵, 森田 明理, 松本 美富士, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 48回,   2004年03月
  • Churg-Strauss症候群の1例, 渡辺 正一, 森田 明理, 辻 卓夫, 難波 大夫, 日本皮膚科学会雑誌, 113, (3) 319 - 319,   2003年03月


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.